Critical elements of clinical follow-up after hospital discharge for heart failure: Insights from the EVEREST trial

European Journal of Heart Failure

Volumn 12, Issue 4, 2010, Pages 367-374

  Dunlay, Shannon M ^a   Gheorghiade, Mihai ^b   Reid, Kimberly J ^c   Allen, Larry A ^d   Chan, Paul S ^c   Hauptman, Paul J ^e   Zannad, Faiez ^f   Maggioni, Aldo P ^g   Swedberg, Karl ^h   Konstam, Marvin A ⁱ   Spertus, John A ^c  

^a MAYO CLINIC ROCHESTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e SAINT LOUIS UNIVERSITY   (United States)

^f INSERM   (France)

^g ANMCO RESEARCH CENTER   (Italy)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ TUFTS MEDICAL CENTER   (United States)

Author keywords

BNP; Health status; Heart failure; Hospitalization; Mortality; Prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN; SODIUM; TOLVAPTAN;

AGED; ARTICLE; CARDIAC PATIENT; CLINICAL EVALUATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG UTILIZATION; FEMALE; FOLLOW UP; FOOT EDEMA; HEALTH STATUS; HEART EJECTION FRACTION; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; HYPONATREMIA; KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RISK FACTOR; SODIUM BLOOD LEVEL;

AGED; BENZAZEPINES; CONFIDENCE INTERVALS; DISEASE PROGRESSION; FEMALE; HEALTH STATUS; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PATIENT DISCHARGE; PATIENT READMISSION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; RECEPTORS, VASOPRESSIN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77950295232     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq019     Document Type: Article

References (34)

1. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007;50:768-777.
2. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009;53: 557-573.
3. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009;360:1418-1428.
4. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004;44:810-819.
5. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. J Am Med Assoc 2004;291:1358-1367.
6. Epstein AM. Revisiting readmissions-changing the incentives for shared accountability. N Engl J Med 2009;360:1457-1459.
7. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-e235.
8. Adams KF, Lindenfeld J, Arnold JM, Massie BM, Baker DW, Mehra MR, Barnard DH, Miller AB. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006;12:e1-e122.
9. Kripalani S, LeFevre F, Phillips CO, Williams MV, Basaviah P, Baker DW. Deficits in communication and information transfer between hospital-based and primary care physicians: implications for patient safety and continuity of care. J Am Med Assoc 2007;297:831-841.
10. Heidenreich PA, Spertus JA, Jones PG, Weintraub WS, Rumsfeld JS, Rathore SS, Peterson ED, Masoudi FA, Krumholz HM, Havranek EP, Conard MW, Williams RE. Health status identifies heart failure outpatients at risk for hospital-ization or death. J Am Coll Cardiol 2006;47:752-756.
11. Soto GE, Jones P, Weintraub WS, Krumholz HM, Spertus JA. Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation 2004;110:546-551.
12. Bonow RO, Bennett S, Casey DE Jr, Ganiats TG, Hlatky MA, Konstam MA, Lambrew CT, Normand SL, Pina IL, Radford MJ, Smith AL, Stevenson LW, Burke G, Eagle KA, Krumholz HM, Linderbaum J, Masoudi FA, Ritchie JL, Rumsfeld JS, Spertus JA. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on performance measures (writing committee to develop heart failure clinical performance measures): endorsed by the Heart Failure Society of America. Circulation 2005;112:1853-1887.
13. Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST). J Card Fail 2005;11:260-269.
14. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. J Am Med Assoc 2007;297:1332-1343.
15. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. Jama 2007;297:1319-1331.
16. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006;107:1747-1750.
17. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245-1255.
18. Chan PS, Soto G, Jones PG, Nallamothu BK, Zhang Z, Weintraub WS, Spertus JA. Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation 2009;119:398-407.
19. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843.
20. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassifica-tion and beyond. Stat Med 2008;27:157-172 (discussion 207-12).
21. Raghunathan TE, Solenberger PW, van Hoewyk J. IVEWARE: imputation and variance estimation software\user guide. Ann Arbor, MI: Survey Research Center, Institute for Social Research; 2002.
22. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, de Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Auricchio A, Bax J, Bohm M, Corra U, della Bella P, Elliott PM, Follath F, Gheorghiade M, Hasin Y, Hernborg A, Jaarsma T, Komajda M, Kornowski R, Piepoli M, Prendergast B, Tavazzi L, Vachiery JL, Verheugt FW, Zannad F. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
23. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). J Am Coll Cardiol 2008;52:347-356.
24. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. J Am Med Assoc 2006;296:2217-2226.
25. Mueller C, Frana B, Rodriguez D, Laule-Kilian K, Perruchoud AP. Emergency diagnosis of congestive heart failure: impact of signs and symptoms. Can J Cardiol 2005; 21:921-924.
26. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:2148-2159.
27. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007;49:1943-1950.
28. Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Anemia and heart failure: a community study. Am J Med 2008;121:726-732.
29. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671-678.
30. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, Felker GM, Adams KF Jr, Califf RM, Gheorghiade M. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the outcomes of a prospective trial of intravenous Mil-rinone for exacerbations of chronic heart failure (OPTIME-CHF) study. Circulation 2005;111:2454-2460.
31. Raphael C, Briscoe C, Davies J, Ian Whinnett Z, Manisty C, Sutton R, Mayet J, Francis DP. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart 2007;93:476-482.
32. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996;94:2800-2806.
33. Hobbs FD, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002;23:1867-1876.
34. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial: prospective randomized evaluation of Carvedilol on symptoms and exercise. Circulation 1996;94:2793-2799.